tradingkey.logo

Pfizer Says Phase 3 EV-304 Clinical Trial Meets Primary Endpoint

ReutersDec 17, 2025 11:52 AM

- PFIZER:

  • PFIZER: PHASE 3 EV-304 TRIAL SHOWED CLINICALLY MEANINGFUL & STATISTICALLY SIGNIFICANT IMPROVEMENTS IN EVENT-FREE SURVIVAL, & OVERALL SURVIVAL

  • PFIZER: PATHOLOGIC COMPLETE RESPONSE RATE FOR NEOADJUVANT PADCEV PLUS PEMBROLIZUMAB VERSUS NEOADJUVANT CHEMOTHERAPY WAS MET

  • PFIZER: PADCEV PLUS KEYTRUDA SIGNIFICANTLY IMPROVES SURVIVAL FOR PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER REGARDLESS OF CISPLATIN ELIGIBILITY

  • PFIZER: SAFETY PROFILE FOR PADCEV PLUS PEMBROLIZUMAB WAS CONSISTENT WITH KNOWN PROFILE OF TREATMENT REGIMEN

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Related Articles

Tradingkey
KeyAI